Samsung Bioepis Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 2012-01-01
- Employees
- 501
- Market Cap
- -
Clinical Trials
78
Active:45
Completed:29
Trial Phases
4 Phases
Phase 1:48
Phase 2:3
Phase 3:13
+1 more phases
Drug Approvals
28
CANADA:14
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (65 trials with phase data)• Click on a phase to view related trials
Phase 1
48 (73.8%)Phase 3
13 (20.0%)Phase 2
3 (4.6%)Phase 4
1 (1.5%)A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 616
- Registration Number
- NCT06348199
- Locations
SB Investigative Site, Sivas, Turkey (Türkiye)
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects with Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
Phase 1
Recruiting
- Conditions
- Non-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage IIIA
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT06268613
- Locations
- 🇹🇷
SB Investigative Site, Istanbul, Turkey
A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
Phase 2
Completed
- Conditions
- Macular EdemaNeovascular Age-related Macular DegenerationRetinal Vein Occlusion
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06176963
- Locations
- 🇵🇱
SB Investigational Site, Olsztyn, Poland
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 4
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: SB5 (Adalimumab Biosimilar)
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 371
- Registration Number
- NCT05510063
- Locations
- 🇵🇱
SB Investigative Site, Świdnik, Poland
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
Phase 3
Completed
- Conditions
- PsoriasisModerate to Severe Plaque Psoriasis
- Interventions
- Drug: SB17 (Proposed Ustekinumab Biosimilar)
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 503
- Registration Number
- NCT04967508
- Locations
- 🇺🇦
SB Investigative Site, Zaporizhzhia, Ukraine
🇪🇪SB investigative site, Tallinn, Estonia
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found